Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 4000 shares traded. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Performance
The firm has a fifty day simple moving average of C$0.02 and a 200-day simple moving average of C$0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The stock has a market cap of C$1.33 million, a price-to-earnings ratio of -1.50 and a beta of 0.05.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last posted its quarterly earnings data on Thursday, August 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The business had revenue of C$0.16 million during the quarter. Analysts forecast that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current fiscal year.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Read More
- Five stocks we like better than Aequus Pharmaceuticals
- EV Stocks and How to Profit from Them
- 3 Momentum Trades for October With Ample Upside Ahead
- What Are Dividend Achievers? An Introduction
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Stock Splits, Do They Really Impact Investors?
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
